



One Luitpold Drive, PO Box 9001, Shirley, New York 11967
(631) 924-4000 • (800) 645-1706 • Fax (631) 924-1731

PRESS RELEASE

FOR IMMEDIATE RELEASE

May 6, 2010

Contact:

American Regent, Inc.
Walter Tozzi, R.Ph., M.S., M.B.A.
Sr. Director of Marketing and Professional Services
631-924-4000
wtozzi@americanregent.com

American Regent announces the availability of Torsemid Injection

Shirley, NY – (May 6, 2010): American Regent, Inc. is pleased to announce that its new product, Torsemide Injection, which was approved by the FDA on April 21, 2010, is now available.

Product	Strength	NDC Number	Shelf Pack
Torsemide Injection	10 mg/mL (2 mL Single Dose Vial)	0517-0770-10	10
Torsemide Injection	10 mg/mL (5 mL Single Dose Vial)	0517-0771-10	10

It is "AP" Rated and is Latex Free.

Headquartered in Shirley, NY, American Regent, Inc., distributes over 80 pharmaceutical products under the PharmaForce or their own label, including Venofer (iron sucrose injection, USP) the #1 selling IV iron therapy in the U.S.

For more information about this product or other American Regent or PharmaForce products, please contact our customer service department at 1-800-645-1706.

Source: American Regent, Inc.

See accompanying Important Safety Information and Full Prescribing Information

IMPORTANT SAFETY INFORMATION

Torsemide Injection is contraindicated in patients who are anuric and in patients with known hypersensitivity to Torsemide or sulfonyleas. Torsemide Injection should be used with caution in patients with hepatic disease with cirrhosis and ascites, as sudden alterations of fluid and electrolyte balance may precipitate hepatic coma. Tinnitus and hearing loss (usually reversible) have been observed after rapid IV injection of other loop diuretics and after oral Torsemide. Periodic monitoring of serum potassium and other electrolytes is advised in patients treated with Torsemide. In placebo controlled trials, the most common side effects considered possibly or probably related to Torsemide Injection were headache (7.3%) excessive urination (6.7%), Dizziness (3.2%), Rhinitis (2.8%), Asthenia (2%), Diarrhea (2%), ECG Abnormality (2%) and Cough Increase (2%).